Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. The abstract of the article is freely available here .The phase II study The phase II trial (NCT03278275) aimed to evaluate the expression of uPAR in neuroendocrine tumor (NET) patients as well as the